#ariba_ref_name	ref_name	gene	var_only	flag	reads	cluster	ref_len	ref_base_assembled	pc_ident	ctg	ctg_len	ctg_cov	known_var	var_type	var_seq_type	known_var_change	has_known_var	ref_ctg_change	ref_ctg_effect	ref_start	ref_end	ref_nt	ctg_start	ctg_end	ctg_nt	smtls_total_depth	smtls_nts	smtls_nts_depth	var_description	free_text
16S.rDNA_WHO_F_01361c	16S.rDNA_WHO_F_01361c	0	1	147	15656	16S	1529	1529	100.0	16S.l15.c4.ctg.1	2033	763.2	1	SNP	n	C1184T	0	.	.	1184	1184	C	1464	1464	C	948	C	889	16S.rDNA_WHO_F_01361c:0:1:C1184T:16S.1184T:E coli C1192T. Resistance to Spectinomycin	.
16S.rDNA_WHO_F_01361c	16S.rDNA_WHO_F_01361c	0	1	147	15656	16S	1529	1529	100.0	16S.l15.c4.ctg.1	2033	763.2	0	HET	.	.	.	C519T,A	.	519	519	C	799	799	C	942	C,T,A	660,214,2	.	.
23S.rDNA_WHO_F_01358c	23S.rDNA_WHO_F_01358c	0	1	659	28344	23S	2890	2890	99.86	23S.l15.c4.ctg.1	3392	830.6	0	.	n	.	0	T695C	SNP	695	695	T	951	951	C	803	C,T	750,1	.	.
23S.rDNA_WHO_F_01358c	23S.rDNA_WHO_F_01358c	0	1	659	28344	23S	2890	2890	99.86	23S.l15.c4.ctg.1	3392	830.6	0	.	n	.	0	G1337A	SNP	1337	1337	G	1593	1593	A	943	A,G	870,1	.	.
23S.rDNA_WHO_F_01358c	23S.rDNA_WHO_F_01358c	0	1	659	28344	23S	2890	2890	99.86	23S.l15.c4.ctg.1	3392	830.6	0	.	n	.	0	T1971C	SNP	1971	1971	T	2227	2227	C	929	C,T	860,1	.	.
23S.rDNA_WHO_F_01358c	23S.rDNA_WHO_F_01358c	0	1	659	28344	23S	2890	2890	99.86	23S.l15.c4.ctg.1	3392	830.6	1	SNP	n	C2597T	1	C2597T	SNP	2597	2597	C	2853	2853	T	880	T,C	832,1	23S.rDNA_WHO_F_01358c:0:1:C2597T:23S.2597T :E coli C2611T. Low-level resistance to Azithromycin	.
23S.rDNA_WHO_F_01358c	23S.rDNA_WHO_F_01358c	0	1	659	28344	23S	2890	2890	99.86	23S.l15.c4.ctg.1	3392	830.6	1	SNP	n	A2045G	0	.	.	2045	2045	A	2301	2301	A	911	A	855	23S.rDNA_WHO_F_01358c:0:1:A2045G:23S.2045G:E coli A2059G. High-level resistance to Azithromycin	.
23S.rDNA_WHO_F_01358c	23S.rDNA_WHO_F_01358c	0	1	659	28344	23S	2890	2890	99.86	23S.l15.c4.ctg.1	3392	830.6	0	HET	.	.	.	G540A,C	.	540	540	G	796	796	G	905	G,A,C	412,408,1	.	.
folP.WHO_P_01364c	folP.WHO_P_01364c	1	1	27	2210	folP	852	852	100.0	folP.l6.c30.ctg.1	1703	129.3	1	SNP	p	R228S	1	.	.	682	684	AGC	1028	1030	AGC	237;235;234	A;G;C	220;219;216	folP.WHO_P_01364c:1:1:R228S:folP.228S:Resistance to sulphonamides	.
gyrA.WHO_F_00668c	gyrA.WHO_F_00668c	1	1	27	6420	gyrA	2751	2751	99.85	gyrA.l15.c4.ctg.1	3401	188.1	1	SNP	p	S91F	0	.	.	271	273	TCC	613	615	TCC	227;227;229	T;C;C	208;209;210	gyrA.WHO_F_00668c:1:1:S91F:gyrA.91F:Resistance to fluoroquinolones	.
gyrA.WHO_F_00668c	gyrA.WHO_F_00668c	1	1	27	6420	gyrA	2751	2751	99.85	gyrA.l15.c4.ctg.1	3401	188.1	1	SNP	p	D95N	0	.	.	283	285	GAC	625	627	GAC	230;228;228	G,A,C;A;C	206,1,1;207;208	gyrA.WHO_F_00668c:1:1:D95N:gyrA.95N:Resistance to fluoroquinolones	.
gyrA.WHO_F_00668c	gyrA.WHO_F_00668c	1	1	27	6420	gyrA	2751	2751	99.85	gyrA.l15.c4.ctg.1	3401	188.1	1	SNP	p	D95G	0	.	.	283	285	GAC	625	627	GAC	230;228;228	G,A,C;A;C	206,1,1;207;208	gyrA.WHO_F_00668c:1:1:D95G:gyrA.95G:Resistance to fluoroquinolones	.
mtrR.WHO_V_01454	mtrR.WHO_V_01454	1	1	539	1726	mtrR	633	633	99.21	mtrR.l15.c4.ctg.1	1251	137.3	0	.	p	.	0	A39T	NONSYN	115	117	GCC	433	435	ACC	208;208;208	A;C;C	189;196;195	.	.
mtrR.WHO_V_01454	mtrR.WHO_V_01454	1	1	539	1726	mtrR	633	633	99.21	mtrR.l15.c4.ctg.1	1251	137.3	0	.	p	.	0	R44H	NONSYN	130	132	CGC	448	450	CAC	203;203;207	C;A;C	187;182;190	.	.
mtrR.WHO_V_01454	mtrR.WHO_V_01454	1	1	539	1726	mtrR	633	633	99.21	mtrR.l15.c4.ctg.1	1251	137.3	0	.	p	.	0	Y105H	NONSYN	313	315	TAC	631	633	CAC	223;220;221	C;A,C;C,A	207;203,1;207,1	.	.
mtrR.WHO_V_01454	mtrR.WHO_V_01454	1	1	539	1726	mtrR	633	633	99.21	mtrR.l15.c4.ctg.1	1251	137.3	1	SNP	p	G45D	0	.	.	133	135	GGC	451	453	GGC	207;209;208	G;G;C	190;190;189	mtrR.WHO_V_01454:1:1:G45D:mtrR.45D:Increased efflux of antimicrobials, e.g. macrolides and b-lactam antimicrobials, that are substrates of the MtrCDE efflux pump	.
mtrR_promoter.WHO_F	mtrR_promoter.WHO_F	0	0	19	1028	mtrR_promoter	250	250	100.0	mtrR_promoter.l15.c30.ctg.1	1049	97.3	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.
parC.WHO_P_00203c	parC.WHO_P_00203c	1	1	27	5836	parC	2304	2304	100.0	parC.l15.c4.ctg.1	2919	198.8	1	SNP	p	D86N	0	.	.	256	258	GAC	437	439	GAC	201;200;202	G;A;C	184;181;186	parC.WHO_P_00203c:1:1:D86N:parC.86N:Resistance to fluoroquinolones	.
parC.WHO_P_00203c	parC.WHO_P_00203c	1	1	27	5836	parC	2304	2304	100.0	parC.l15.c4.ctg.1	2919	198.8	1	SNP	p	S87W	0	.	.	259	261	AGT	440	442	AGT	201;200;201	A,C;G;T	189,1;187;190	parC.WHO_P_00203c:1:1:S87W:parC.87W:Resistance to fluoroquinolones	.
parC.WHO_P_00203c	parC.WHO_P_00203c	1	1	27	5836	parC	2304	2304	100.0	parC.l15.c4.ctg.1	2919	198.8	1	SNP	p	S87I	0	.	.	259	261	AGT	440	442	AGT	201;200;201	A,C;G;T	189,1;187;190	parC.WHO_P_00203c:1:1:S87I:parC.87I:Resistance to fluoroquinolones	.
parC.WHO_P_00203c	parC.WHO_P_00203c	1	1	27	5836	parC	2304	2304	100.0	parC.l15.c4.ctg.1	2919	198.8	1	SNP	p	S87R	0	.	.	259	261	AGT	440	442	AGT	201;200;201	A,C;G;T	189,1;187;190	parC.WHO_P_00203c:1:1:S87R:parC.87R:Resistance to fluoroquinolones	.
parC.WHO_P_00203c	parC.WHO_P_00203c	1	1	27	5836	parC	2304	2304	100.0	parC.l15.c4.ctg.1	2919	198.8	1	SNP	p	S88P	0	.	.	262	264	TCC	443	445	TCC	202;203;205	T;C;C	187;190;193	parC.WHO_P_00203c:1:1:S88P:parC.88P:Resistance to fluoroquinolones	.
parE.WHO_F_01528c	parE.WHO_F_01528c	1	1	27	4754	parE	1986	1986	100.0	parE.l15.c4.ctg.1	2516	187.7	1	SNP	p	G410V	0	.	.	1228	1230	GGC	1451	1453	GGC	222;222;224	G,A;G;C,A	196,1;198;198,1	parE.WHO_F_01528c:1:1:G410V:parE.410V:Resistance to fluoroquinolones	.
penA.2.001	penA.2.001	1	1	27	4376	penA	1749	1749	100.0	penA.l15.c17.ctg.1	2347	184.9	1	SNP	p	A311V	0	.	.	931	933	GCA	1126	1128	GCA	225;225;226	G;C;A	209;209;214	penA.2.001:1:1:A311V:penA.311V:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.2.001	penA.2.001	1	1	27	4376	penA	1749	1749	100.0	penA.l15.c17.ctg.1	2347	184.9	1	SNP	p	I312M	0	.	.	934	936	ATC	1129	1131	ATC	226;225;227	A;T;C	213;211;212	penA.2.001:1:1:I312M:penA.312M:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.2.001	penA.2.001	1	1	27	4376	penA	1749	1749	100.0	penA.l15.c17.ctg.1	2347	184.9	1	SNP	p	V316P	0	.	.	946	948	GTG	1141	1143	GTG	228;226;226	G;T;G	216;215;215	penA.2.001:1:1:V316P:penA.316P:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.2.001	penA.2.001	1	1	27	4376	penA	1749	1749	100.0	penA.l15.c17.ctg.1	2347	184.9	1	SNP	p	V316T	0	.	.	946	948	GTG	1141	1143	GTG	228;226;226	G;T;G	216;215;215	penA.2.001:1:1:V316T:penA.316T:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.2.001	penA.2.001	1	1	27	4376	penA	1749	1749	100.0	penA.l15.c17.ctg.1	2347	184.9	1	SNP	p	T484S	0	.	.	1450	1452	ACC	1645	1647	ACC	258;256;257	A;C;C	231;230;229	penA.2.001:1:1:T484S:penA.483S:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.2.001	penA.2.001	1	1	27	4376	penA	1749	1749	100.0	penA.l15.c17.ctg.1	2347	184.9	1	SNP	p	A502P	0	.	.	1504	1506	GCG	1699	1701	GCG	247;246;243	G;C;G	211;195;202	penA.2.001:1:1:A502P:penA.501P:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.2.001	penA.2.001	1	1	27	4376	penA	1749	1749	100.0	penA.l15.c17.ctg.1	2347	184.9	1	SNP	p	A502V	0	.	.	1504	1506	GCG	1699	1701	GCG	247;246;243	G;C;G	211;195;202	penA.2.001:1:1:A502V:penA.501V:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.2.001	penA.2.001	1	1	27	4376	penA	1749	1749	100.0	penA.l15.c17.ctg.1	2347	184.9	1	SNP	p	G543S	0	.	.	1627	1629	GGC	1822	1824	GGC	222;222;221	G;G;C	202;201;201	penA.2.001:1:1:G543S:penA.542S:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.2.001	penA.2.001	1	1	27	4376	penA	1749	1749	100.0	penA.l15.c17.ctg.1	2347	184.9	1	SNP	p	G546S	0	.	.	1636	1638	GGC	1831	1833	GGC	215;215;211	G;G;C	197;193;191	penA.2.001:1:1:G546S:penA.545S:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.2.001	penA.2.001	1	1	27	4376	penA	1749	1749	100.0	penA.l15.c17.ctg.1	2347	184.9	1	SNP	p	P552S	0	.	.	1654	1656	CCG	1849	1851	CCG	193;197;199	C,G;C;G	143,8;145;146	penA.2.001:1:1:P552S:penA.551S:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
ponA.WHO_F_00106	ponA.WHO_F_00106	1	1	27	6114	ponA	2397	2397	99.96	ponA.l15.c17.ctg.1	2991	203.3	1	SNP	p	L421P	0	.	.	1261	1263	CTG	1524	1526	CTG	217;217;219	C;T;G	197;193;196	ponA.WHO_F_00106:1:1:L421P:ponA.421P:High-level chromosomally-mediated penicillin resistance	.
porA.NCCP11945	porA.NCCP11945	1	0	531	2670	porA	1146	1146	99.83	porA.l15.c4.ctg.1	1778	149.4	0	.	p	.	0	M83fs	FSHIFT	247	247	A	525	525	C	176	C	164	.	.
porB1b.WHO_U_02278c	porB1b.WHO_U_02278c	1	1	539	2772	porB1b	1035	1035	95.82	porB1b.l15.c17.ctg.1	1520	181.4	0	.	p	.	0	E48G	NONSYN	142	144	GAA	466	468	GGA	259;261;260	G;G,A;A	241;240,1;239	.	.
porB1b.WHO_U_02278c	porB1b.WHO_U_02278c	1	1	539	2772	porB1b	1035	1035	95.82	porB1b.l15.c17.ctg.1	1520	181.4	0	.	p	.	0	F135L	NONSYN	403	405	TTT	727	729	CTT	197;198;202	C;T;T	184;183;185	.	.
porB1b.WHO_U_02278c	porB1b.WHO_U_02278c	1	1	539	2772	porB1b	1035	1035	95.82	porB1b.l15.c17.ctg.1	1520	181.4	0	.	p	.	0	R143G	NONSYN	427	429	AGA	751	753	GGA	187;187;188	G;G;A	175;176;171	.	.
porB1b.WHO_U_02278c	porB1b.WHO_U_02278c	1	1	539	2772	porB1b	1035	1035	95.82	porB1b.l15.c17.ctg.1	1520	181.4	0	.	p	.	0	D171G	NONSYN	511	513	GAT	835	837	GGT	205;205;207	G;G;T	191;192;187	.	.
porB1b.WHO_U_02278c	porB1b.WHO_U_02278c	1	1	539	2772	porB1b	1035	1035	95.82	porB1b.l15.c17.ctg.1	1520	181.4	0	.	p	.	0	G189S	NONSYN	565	567	GGC	889	891	AGC	222;223;223	A;G;C	197;198;195	.	.
porB1b.WHO_U_02278c	porB1b.WHO_U_02278c	1	1	539	2772	porB1b	1035	1035	95.82	porB1b.l15.c17.ctg.1	1520	181.4	0	.	p	.	0	Y211fs	FSHIFT	631	631	T	955	955	T	205	T	196	.	.
porB1b.WHO_U_02278c	porB1b.WHO_U_02278c	1	1	539	2772	porB1b	1035	1035	95.82	porB1b.l15.c17.ctg.1	1520	181.4	1	SNP	p	G120K	0	.	.	358	360	GGT	682	684	GGT	201;198;199	G;G;T	188;187;184	porB1b.WHO_U_02278c:1:1:G120K:porB1b.120K:G101K. Mediates decreased permeability of antimicrobials through the porin PorB1b	.
porB1b.WHO_U_02278c	porB1b.WHO_U_02278c	1	1	539	2772	porB1b	1035	1035	95.82	porB1b.l15.c17.ctg.1	1520	181.4	1	SNP	p	A121D	0	.	.	361	363	GCC	685	687	GCC	197;198;199	G;C;C	184;188;189	porB1b.WHO_U_02278c:1:1:A121D:porB1b.121D:A102D. Mediates decreased permeability of antimicrobials through the porin PorB1b	.
porB1b.WHO_U_02278c	porB1b.WHO_U_02278c	1	1	539	2772	porB1b	1035	1035	95.82	porB1b.l15.c17.ctg.1	1520	181.4	1	SNP	p	A121N	0	.	.	361	363	GCC	685	687	GCC	197;198;199	G;C;C	184;188;189	porB1b.WHO_U_02278c:1:1:A121N:porB1b.121N:A102N. Mediates decreased permeability of antimicrobials through the porin PorB1b	.
rpoB.WHO_M_02157	rpoB.WHO_M_02157	1	1	27	11136	rpoB	4179	4179	100.0	rpoB.l15.c4.ctg.1	4981	222.8	1	SNP	p	H553N	1	.	.	1657	1659	AAT	2093	2095	AAT	255;257;259	A,C;A;T	233,3;238;238	rpoB.WHO_M_02157:1:1:H553N:rpoB.553N:H552N. High-level resistance to Rifampicin	.
rpsJ.WHO_Y_02241	rpsJ.WHO_Y_02241	1	1	27	1152	rpsJ	312	312	100.0	rpsJ.l15.c17.ctg.1	1036	110.5	1	SNP	p	V57M	1	.	.	169	171	ATG	534	536	ATG	241;244;242	A;T;G	220;224;220	rpsJ.WHO_Y_02241:1:1:V57M:rpsJ.57M:Chromosomally-mediated resistance to tetracyclines	.
